Endologix (NASDAQ:ELGX) was downgraded by stock analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research report issued to clients and investors on Tuesday.
ELGX has been the topic of a number of other research reports. Royal Bank of Canada cut their price objective on shares of Endologix from $5.00 to $4.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 8th. Stifel Nicolaus set a $6.00 price objective on shares of Endologix and gave the stock a “hold” rating in a report on Friday, October 6th. BidaskClub cut shares of Endologix from a “buy” rating to a “hold” rating in a report on Friday, December 15th. ValuEngine cut shares of Endologix from a “sell” rating to a “strong sell” rating in a report on Sunday. Finally, Canaccord Genuity restated a “hold” rating and issued a $5.00 price objective on shares of Endologix in a report on Wednesday, September 27th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $5.41.
Shares of Endologix (NASDAQ ELGX) opened at $5.35 on Tuesday. The firm has a market cap of $446.48, a PE ratio of -5.75 and a beta of 0.72. The company has a quick ratio of 2.11, a current ratio of 2.90 and a debt-to-equity ratio of 2.61. Endologix has a fifty-two week low of $4.08 and a fifty-two week high of $7.66.
COPYRIGHT VIOLATION NOTICE: “JPMorgan Chase & Co. Lowers Endologix (ELGX) to Underweight” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2018/01/02/jpmorgan-chase-co-lowers-endologix-elgx-to-underweight.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.